Concentration of vascular endothelial growth factor released by cultured human luteinized granulosa cells is higher in women with polycystic ovaries than in women with normal ovaries.
To test the hypothesis that increased serum levels of vascular endothelial growth factor (VEGF) in women with polycystic ovaries or the polycystic ovary syndrome (PCOS) result from excess release by ovarian granulosa cells. Prospective study. Academic research setting. Twenty women undergoing IVF treatment, of whom 10 had normal ovaries and 10 had polycystic ovaries. Human granulosa lutein cells were isolated from follicular fluid obtained on the day of oocyte retrieval. Release of VEGF was assessed after co-incubation of granulosa lutein cells with gonadotropins and insulin. Serum and follicular fluid concentrations of VEGF were measured. Release of VEGF from granulosa lutein cells and serum levels of VEGF. Incubation with human hCG, and luteinizing hormone increased release of VEGF into the culture medium. Insulin alone did not increase release of VEGF, but addition of insulin increased hCG-stimulated release of VEGF. Serum and follicular fluid VEGF concentrations and the amount VEGF released from granulosa lutein cells obtained from women with polycystic ovaries or PCOS and those who developed the ovarian hyperstimulation syndrome were greater than those from granulosa lutein cells obtained from women with normal ovaries and those who did not develop the ovarian hyperstimulation syndrome. The amount of VEGF released by granulosa lutein cells is gonadotropin dependent and is augmented by insulin. The increased circulating concentrations of VEGF in women with PCOS may not only be due to an increased number of actively secreting granulosa lutein cells but also due to increased secretory capacity of each granulosa cell.
Agrawal
Rina
R
Department of Reproductive Endocrinology, Cobbold Laboratories, The Middlesex Hospital, London, United Kingdom. ganapaty@dircon.co.uk
Jacobs
Howard
H
Payne
Nadia
N
Conway
Gerard
G
D000328:Adult; D001769:Blood / Q000378:metabolism; D002478:Cells, Cultured; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D016228:Endothelial Growth Factors / Q000378:metabolism*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000494:pharmacology; D015571:Follicular Fluid / Q000378:metabolism; D006107:Granulosa Cells / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism*; D034461:Luteinization / Q000502:physiology*; D007986:Luteinizing Hormone / Q000494:pharmacology; D008222:Lymphokines / Q000378:metabolism*; D009994:Osmolar Concentration; D011085:Polycystic Ovary Syndrome / Q000378:metabolism* / Q000503:physiopathology; D011446:Prospective Studies; D012016:Reference Values; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D006063:Chorionic Gonadotropin; D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone